Who Paid My Doc
Samer Thanavaro
Cardiovascular Disease Saint Louis, MO Medical Doctor
NPI 1619960606 CMS profile 163705
11125 Dunn Rd, Suite 204, Saint Louis, MO 63136
General payments
$3,708
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Samer Thanavaro of Saint Louis, MO is reported in the CMS Open Payments database as having received $3,708 across 239 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 62nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $152 | 2 | |
| 2023 | General | $462 | 27 | |
| 2022 | General | $804 | 49 | |
| 2021 | General | $886 | 61 | |
| 2020 | General | $584 | 44 | |
| 2019 | General | $819 | 56 |
Beside peers
- Samer Thanavaro
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Samer Thanavaro were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Samer Thanavaro | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $819 | $450 | $127–$1,392 | $163 |
| 2020 | $584 | $242 | $77–$751 | $114 |
| 2021 | $886 | $335 | $101–$1,037 | $132 |
| 2022 | $804 | $395 | $121–$1,211 | $149 |
| 2023 | $462 | $443 | $136–$1,283 | $160 |
| 2024 | $152 | $450 | $136–$1,323 | $164 |
| 2025 | $0 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 37 drugsPart D claims
2,388
Drug cost
$512,559
Branded share of claims
31.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 299 | $269,248 | |
| Xarelto Rivaroxaban | Brand | 105 | $103,372 | |
| Entresto Sacubitril/Valsartan | Brand | 82 | $81,777 | |
| Jardiance Empagliflozin | Brand | 19 | $13,796 | |
| Farxiga Dapagliflozin Propanediol | Brand | 22 | $12,818 | |
| Ranolazine Er Ranolazine | Brand | 37 | $5,333 | |
| Metoprolol Succinate | Generic | 237 | $3,752 | |
| Midodrine Hcl | Generic | 25 | $3,453 | |
| Atorvastatin Calcium | Generic | 141 | $1,664 | |
| Amiodarone Hcl | Generic | 97 | $1,543 |
The 10 drugs with the highest cost, of 37 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
239 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Missouri
Mikhail Kosiborod
Cardiovascular Disease · Kansas City, MO
Georges Chahoud
Cardiovascular Disease · Saint Louis, MO
William Bowen
Cardiovascular Disease · Saint Louis, MO
Daniel Kelly
Cardiovascular Disease · Saint Louis, MO
John Spertus
Cardiovascular Disease · Kansas City, MO
James Fairlamb
Cardiovascular Disease · Columbia, MO
Related records
Cardiovascular Disease in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.